May 1 (Reuters) – The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas’ breast cancer drug for patients with an advanced form of the disease whose tumors carry a specific genetic mutation.
The drug, to be sold under the brand name of Veppanu, is approved for adults with estrogen receptor-positive, HER2-negative breast cancer that has spread or cannot be removed by surgery.
Patients must have an ESR1 mutation and must have seen their cancer worsen after at least one prior hormone treatment, the agency said.
Shares of Arvinas rose 3.7% in afternoon trading, while Pfizer’s stock was down about 1%.
(Reporting by Sriparna Roy and Kamal Choudhury in Bengaluru; Editing by Shreya Biswas)
Comments